Capital Fund Management S.A. Raises Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

Capital Fund Management S.A. boosted its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 130.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,488 shares of the company's stock after purchasing an additional 21,762 shares during the quarter. Capital Fund Management S.A.'s holdings in Biohaven were worth $1,438,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the business. HighTower Advisors LLC raised its position in shares of Biohaven by 6.1% in the 4th quarter. HighTower Advisors LLC now owns 5,870 shares of the company's stock worth $219,000 after acquiring an additional 335 shares in the last quarter. Franklin Resources Inc. grew its position in Biohaven by 0.5% during the 3rd quarter. Franklin Resources Inc. now owns 79,705 shares of the company's stock worth $4,206,000 after purchasing an additional 412 shares during the last quarter. FSC Wealth Advisors LLC increased its stake in Biohaven by 3.3% during the 4th quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company's stock valued at $579,000 after purchasing an additional 500 shares in the last quarter. Prudential Financial Inc. raised its holdings in shares of Biohaven by 9.4% in the fourth quarter. Prudential Financial Inc. now owns 5,980 shares of the company's stock worth $223,000 after buying an additional 514 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in shares of Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock valued at $109,000 after acquiring an additional 527 shares during the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director John W. Childs purchased 32,700 shares of Biohaven stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now directly owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 16.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on BHVN. HC Wainwright reaffirmed a "buy" rating and issued a $54.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Morgan Stanley dropped their target price on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on shares of Biohaven and gave the stock a "buy" rating in a research note on Thursday, March 20th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. Fourteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $62.77.

Biohaven Stock Performance

Shares of BHVN traded up $1.73 during trading hours on Friday, hitting $20.41. 2,098,008 shares of the stock were exchanged, compared to its average volume of 1,110,098. The stock's 50-day moving average price is $28.43 and its two-hundred day moving average price is $38.58. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -2.18 and a beta of 1.33. Biohaven Ltd. has a 12-month low of $15.79 and a 12-month high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). On average, research analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.